CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
This explains the function of the index divisor for investors, including how it influences observed returns and analysis.
26,233 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
A stock down 2026 can still offer surprises. This guide breaks down bear, base, and bull scenarios for the next three...
Celsius is already generating strong margins, and that has investors rethinking how high profits could go. This artic...
Qualcomm is pivoting from phones to AI chips and software, aiming to blend edge intelligence with data-center power. ...
Three energy-focused ETFs are delivering roughly 7% yields in 2026 while avoiding K-1 tax forms. They promise simpler...
When an energy storage company reports stronger results, the market often reacts with a sharp stock move. This guide ...
Tensions around Yemen’s Houthis could disrupt a key oil route and set off a chain reaction in markets. This guide exp...
Get a clear, investor-friendly view of Perion's 2025 earnings outlook. This guide explains revenue drivers, margins, ...
C3.AI reports two consecutive quarterly revenue declines, forcing investors to reassess its enterprise AI strategy as...
This in-depth look examines the factors behind wallbox (wbx) 2025 earnings and what they mean for investors. Learn ab...
Newmont Corporation stock dropped today as macro data and gold price moves rattled investors. This guide explains the...
A veteran deputy abused his badge to pressure crypto rivals, landing him a multi-year prison term. This case spotligh...